POLE

Across TCGA pan-cancer cohorts, POLE mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLE data layer compared with 27 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POLE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated POLE expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where POLE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.957	0.601	.002	31	view →
HNSC	OS	Median	All	1.000	0.377	.032	6	view →
CCRCC	OS	Tertile	II,III,IV	0.970	0.519	.020	2	view →
LUAD	OS	Quartile	III,IV	0.450	0.821	.018	2	view →
GBM	OS	Quartile	All	0.829	0.454	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POLE–LSCC (OS)

Open the LSCC breakdown →